US Autoimmune Disease Diagnostics Market, Forecast to 2020

Systemic Autoimmune Diseases to Spur Double-digit Market Growth as Participants Look to Unmet Needs and Game-changing Strategies to Boost Revenues

USD 1,500

* Required Fields

USD 1,500

PAY BY INVOICE

Be the first to review this product

According to the National Institute of Health (NIH), there are more than 80 types of autoimmune diseases, of which less than 30 are diagnosable. Being 1 of the top 10 causes of death in the United States, there is a critical need in the market for the diagnosis and the treatment of both systemic diseases, such as lupus and rheumatoid arthritis, as well as localized diseases, such as celiac, IBD, IBS, and Hashimoto's. Systemic diseases dominate the market due to their high prevalence in the United States and also because of the market participation of large diagnostics companies, such as Inova Diagnostics, Siemens Healthcare, Abbott Diagnostics, and Beckman Coulter. The localized disease segment is the fastest-growing, mainly due to celiac, as gluten intolerance in the United States is increasing at an exponential rate.

Table of Contents

US Autoimmune Disease Diagnostics Market, Forecast to 2020Executive SummaryScope and SegmentationKey Predictions: US Autoimmune Disease Diagnostics MarketCurrent Trends in the Autoimmune Disease Diagnostics MarketAutoimmune Disease Diagnostics Market—Overview Key Companies to WatchCompetitive OverviewEcosystem of the Autoimmune Disease Diagnostics MarketSignificance of the Autoimmune Disease Diagnostics MarketSignificance of the Autoimmune Disease Diagnostics Market—Prevalence RatesCompetitive LandscapeKey Diseases and Available Solutions in the US MarketKey Diseases and Available Solutions in the US Market (continued)LDTs—Role in Autoimmune Disease DiagnosticsSegment Lifecycle Analysis by DiseaseOverall Market ForecastOverall Disease Segment ShareCompetitive SWOT Analysis by CompanyCompetitive SWOT Analysis by Company (continued)Growth OpportunitiesWhere do the Opportunities Lie in this Market?Pharma and Diagnostics Business IntegrationAutoimmune Diagnostics Companies are Uniting with Pharmaceuticals to Diversify Revenue ChannelsDirect-to-Consumer Market: The Risk and The OpportunityLocalized Disease Diagnostics SegmentLocalized Disease Diagnostics Segment RevenueGrowth Rate by Localized Autoimmune DiseasesCompetitive Value Matrix—Localized Disease Diagnostics SegmentAutoimmune Tests—Role in Patient ContinuumSystemic Disease Diagnostics SegmentSystemic Disease Diagnostics Segment RevenueGrowth Rate by Systemic Autoimmune DiseasesCompetitive Value Matrix—Systemic Disease Diagnostics SegmentAutoimmune Tests—Role in Patient ContinuumConclusionKey Conclusions and Future OutlookLegal DisclaimerAppendix—List of LDTsCeliac Disease-specific LDT AssaysChron’s Disease-specific LDT AssaysRA-specific LDT AssaysLupus-specific LDT AssaysIBD/IBS-specific LDT AssaysOthersLearn More—Next StepsList of ExhibitsList of Exhibits (continued)List of Exhibits (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Release Date : 18-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Release Date : 15-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.